CEBPA and acute myeloid leukemia: Overall, our results demonstrate that the delivery of CEBPA-51 saRNA into AML cell lines and patient-derived cells in vivo is feasible, leading to a significant upregulation of C/EBPα and enhanced therapeutic effect of gilteritinib in an AML mouse model.